Kane Biotech Inc. (KNE.V)

CAD 0.1

(0.0%)

Long Term Debt Summary of Kane Biotech Inc.

  • Kane Biotech Inc.'s latest annual long term debt in 2023 was 1.3 Million CAD , down -49.49% from previous year.
  • Kane Biotech Inc.'s latest quarterly long term debt in 2024 Q2 was 1.95 Million CAD , down -6.92% from previous quarter.
  • Kane Biotech Inc. reported annual long term debt of 2.57 Million CAD in 2022, up 17.04% from previous year.
  • Kane Biotech Inc. reported annual long term debt of 2.2 Million CAD in 2021, up 219.24% from previous year.
  • Kane Biotech Inc. reported quarterly long term debt of 1.95 Million CAD for 2024 Q2, down -6.92% from previous quarter.
  • Kane Biotech Inc. reported quarterly long term debt of 1.3 Million CAD for 2023 Q4, down -43.11% from previous quarter.

Annual Long Term Debt Chart of Kane Biotech Inc. (2023 - 2003)

Historical Annual Long Term Debt of Kane Biotech Inc. (2023 - 2003)

Year Long Term Debt Long Term Debt Growth
2023 1.3 Million CAD -49.49%
2022 2.57 Million CAD 17.04%
2021 2.2 Million CAD 219.24%
2020 690.17 Thousand CAD 321.81%
2019 163.62 Thousand CAD 0.0%
2018 - CAD 0.0%
2017 - CAD -100.0%
2016 29.97 Thousand CAD -93.17%
2015 438.64 Thousand CAD 0.0%
2014 - CAD -100.0%
2013 413.24 Thousand CAD 0.0%
2012 - CAD 0.0%
2011 - CAD 0.0%
2010 - CAD 0.0%
2009 - CAD 0.0%
2008 - CAD 0.0%
2007 - CAD 0.0%
2006 - CAD 0.0%
2005 - CAD 0.0%
2004 - CAD 0.0%
2003 - CAD 0.0%

Peer Long Term Debt Comparison of Kane Biotech Inc.

Name Long Term Debt Long Term Debt Difference
Arch Biopartners Inc. 703.92 Thousand CAD -85.03%
Covalon Technologies Ltd. 919.08 Thousand CAD -41.714%
Hemostemix Inc. 4.32 Million CAD 69.861%
Universal Ibogaine Inc. 1.73 Million CAD 25.046%
MedMira Inc. 2.95 Million CAD 55.957%
Marvel Biosciences Corp. 1 Million CAD -30.246%
NervGen Pharma Corp. 105.6 Thousand CAD -1133.346%
XORTX Therapeutics Inc. - CAD -Infinity%